Reneo Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Reneo Pharmaceuticals (NASDAQ: RPHM) announced its participation in two upcoming investor conferences in November 2021. The Credit Suisse 30th Annual Healthcare Conference will be held from November 8-11, where Reneo will present on November 11 from 12:10 to 12:50 PM ET. Additionally, Reneo will participate in the Piper Sandler 33rd Healthcare Conference from November 30 to December 2, with an on-demand fireside chat scheduled for November 22. Reneo focuses on therapies for rare genetic mitochondrial diseases, specifically developing REN001 to enhance mitochondrial function.

IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be participating in the following investors conferences during the month of November.

Conference and presentation details are as follows:

Credit Suisse 30^th Annual Healthcare Conference (November 8-11, 2021)
Format: Presentation and one-on-one’s
Date: Thursday, November 11^th, 2021
Time: 12:10-12:50 PM ET

Piper Sandler 33rd Healthcare Conference (November 30-December 2, 2021)
Format: Fireside chat (on-demand)
Date: Monday, November 22^nd, 2021

A link to our presentation from the Credit Suisse Healthcare Conference will be posted on the “Investors” section of the Reneo Pharmaceuticals corporate website, under Events and Presentations.

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com

FAQ

When will Reneo Pharmaceuticals present at the Credit Suisse Healthcare Conference?

Reneo Pharmaceuticals will present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021, from 12:10 to 12:50 PM ET.

What is the date for Reneo Pharmaceuticals' fireside chat at the Piper Sandler Healthcare Conference?

Reneo Pharmaceuticals' fireside chat at the Piper Sandler 33rd Healthcare Conference is scheduled for November 22, 2021.

What is the focus of Reneo Pharmaceuticals?

Reneo Pharmaceuticals focuses on developing therapies for patients with rare genetic mitochondrial diseases.

What is REN001 being developed for by Reneo Pharmaceuticals?

REN001 is being developed by Reneo Pharmaceuticals to enhance mitochondrial function and increase ATP production.

Where can I find Reneo Pharmaceuticals' presentation from the Credit Suisse conference?

Reneo Pharmaceuticals' presentation from the Credit Suisse Healthcare Conference will be available in the 'Investors' section of their corporate website.